MGK wrote, "Scott Kelly couldn't have been more cl
Post# of 148331
Quote:
But there’s a very high bar for a breakthrough designation, and we don’t believe that’s enough data. So we will be progressing this molecule forward for mTNBC and looking for more development opportunities.
I'm not sure that's clear at all.
There's not enough data for BTD. Okay. Why not? The data stops at the 12-month mark? There aren't enough patients? The improvement over Trodelvy isn't sharp enough?
We will be progressing LL forward for mTNBC. How? Through more trials? More analysis of the data we have? Partnership?
Since we haven't heard anything about more trials or more data in the past six months, maybe we can assume he means partnership. Maybe. It would be nice to know.